All In Biotech

Drug Trial Radar · NCT06227832

A Study to Determine the Effect of KP-001 on Metformin and Midazolam Pharmacokinetics and the Effect of Clarithromycin on KP-001 Pharmacokinetics in Healthy Adult Participants

An Open-label Study to Determine the Effect of Oral Doses of KP-001 on Metformin and Midazolam Pharmacokinetics After a Single Oral Administration and to Determine the Effect of Clarithromycin on KP-001 Pharmacokinetics After a Single Oral Administration in Healthy Adult Participants

Last checked: Nov 19, 2026Latest source record: Mar 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

38

Actual

Start

Dec 15, 2023

Primary completion

Mar 15, 2024

Study completion Jul 31, 2024

Sponsor

Lead sponsor
Kaken PharmaceuticalIndustry
Sponsor type
Industry
First posted
Jan 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the Effects of KP-001 on Metformin (a substrate of MATE1) and Midazolam (a substrate of CYP3A4) Pharmacokinetics and the Effect of Clarithromycin (potent CYP3A4/P-gp Inhibitor) on KP-001 Pharmacokinetics in Healthy Adult Participants. The study will also evaluate the safety and tolerability of KP-001 with and without a single dose or multiple doses of an interaction drug. The study comprises 3 parts. Participants will stay in the Clinical Unit during the study, depending on which part they assigned to. Participants will remain at the clinical site for a 13 day/12 night in-house stay (Part 1), a 14 day/13 night in house stay (Part 2), or a 11 day/10 night in-house stay (Part 3).

Conditions

  • Healthy Adults

Interventions

  • KP-001Drug

    KP-001

  • MetforminDrug

    oral dose of 850 mg Metformin

  • MidazolamDrug

    oral dose of 2 mg Midazolam

  • ClarithromycinDrug

    oral doses of 1000 mg Clarithromycin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetic (PK) parameters of metformin in plasma: Area under the concentration-time curve from time 0 extrapolated to infinite time (AUCinf)Time frame: 13 days
  2. PK parameters of midazolam in plasma: AUCinfTime frame: 14 days
  3. PK parameters of KP-001 in plasma: AUCinfTime frame: 11 days
  4. PK parameters of metformin in plasma: Maximum observed concentration (Cmax)Time frame: 13 days
  5. PK parameters of midazolam in plasma: CmaxTime frame: 14 days
  6. PK parameters of KP-001 in plasma: CmaxTime frame: 11 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Parexel Early Phase Clinical Unit - Los Angeles

    Glendale, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.